We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Earlier this week, Arena Pharmaceuticals, Inc.’ shares rose 34 percent in premarket trading after the company released positive top-line results from its Phase II trial of etrasimod in ulcerative colitis (UC).
US-based Arena Pharmaceuticals formed a development and commercialisation alliance with Chinese C-Bridge Capital-backed Everest Medicines for offering ralinepag and etrasimod in selected Asian countries.